These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
| Tennessee | 62-1443555 | |
| (State or other jurisdiction of | (I.R.S. Employer Identification No.) | |
| incorporation or organization) | ||
| 209 10th Avenue South, Suite 450 | ||
| Nashville, Tennessee | 37203 | |
| (Address of principal executive offices) | (Zip Code) |
| Large accelerated filer o | Accelerated filer o | Non-accelerated filer o | Smaller reporting company þ | |||
| (Do not check if a smaller reporting company) |
| March 31, | December 31, | |||||||
| 2011 | 2010 | |||||||
| (Unaudited) | ||||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$ | 14,220,351 | $ | 17,867,860 | ||||
|
Investments in short-term marketable securities
|
8,261,843 | 5,703,192 | ||||||
|
Restricted cash
|
124,550 | 84,528 | ||||||
|
Interest receivable
|
47,341 | 51,226 | ||||||
|
Accounts receivable, net of allowance for doubtful accounts of $126,686
and $156,723 at March 31, 2011 and December 31, 2010, respectively
|
13,046,474 | 11,069,108 | ||||||
|
Accounts receivable unbilled
|
1,411,495 | 1,314,025 | ||||||
|
Deferred tax assets, current
|
3,436,671 | 3,436,671 | ||||||
|
Prepaid royalties, net of amortization
|
2,403,826 | 3,145,297 | ||||||
|
Other prepaid expenses and other current assets
|
1,687,470 | 1,598,874 | ||||||
|
|
||||||||
|
Total current assets
|
44,640,021 | 44,270,781 | ||||||
|
Property and equipment:
|
||||||||
|
Equipment
|
14,424,732 | 14,347,683 | ||||||
|
Leasehold improvements
|
3,289,512 | 2,737,715 | ||||||
|
Furniture and fixtures
|
1,958,141 | 2,027,535 | ||||||
|
|
||||||||
|
|
19,672,385 | 19,112,933 | ||||||
|
Less accumulated depreciation and amortization
|
(15,447,703 | ) | (15,287,579 | ) | ||||
|
|
||||||||
|
|
4,224,682 | 3,825,354 | ||||||
|
|
||||||||
|
Capitalized software development, net of accumulated amortization of
$6,324,760 and $5,886,594 at March 31, 2011 and December 31, 2010, respectively
|
7,980,887 | 4,332,705 | ||||||
|
Goodwill
|
21,146,864 | 21,146,864 | ||||||
|
Intangible assets, net of accumulated amortization of $8,276,216
and $8,043,328 at March 31, 2011 and December 31, 2010, respectively
|
2,610,926 | 2,843,814 | ||||||
|
Deferred tax assets, noncurrent
|
4,295,125 | 5,346,536 | ||||||
|
Other assets
|
191,022 | 244,649 | ||||||
|
|
||||||||
|
Total assets
|
$ | 85,089,527 | $ | 82,010,703 | ||||
|
|
||||||||
|
|
||||||||
|
LIABILITIES AND SHAREHOLDERS EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$ | 1,374,734 | $ | 2,374,621 | ||||
|
Accrued liabilities
|
3,631,848 | 4,120,786 | ||||||
|
Accrued compensation and related expenses
|
796,532 | 1,506,245 | ||||||
|
Deferred revenue
|
20,082,512 | 16,740,454 | ||||||
|
Capital lease obligations
|
2,753 | 4,362 | ||||||
|
|
||||||||
|
Total current liabilities
|
25,888,379 | 24,746,468 | ||||||
|
|
||||||||
|
Other long-term liabilities
|
492,572 | 473,897 | ||||||
|
Commitments and contingencies
|
| | ||||||
|
|
||||||||
|
Shareholders equity:
|
||||||||
|
Common stock, no par value, 75,000,000 shares authorized;
21,931,535 and 21,805,235 shares issued and outstanding
at March 31, 2011 and December 31, 2010, respectively
|
97,615,980 | 97,227,198 | ||||||
|
Accumulated deficit
|
(38,905,686 | ) | (40,431,443 | ) | ||||
|
Accumulated other comprehensive loss
|
(1,718 | ) | (5,417 | ) | ||||
|
|
||||||||
|
Total shareholders equity
|
58,708,576 | 56,790,338 | ||||||
|
|
||||||||
|
Total liabilities and shareholders equity
|
$ | 85,089,527 | $ | 82,010,703 | ||||
|
|
||||||||
1
| Three Months Ended March 31, | ||||||||
| 2011 | 2010 | |||||||
|
Revenues, net
|
$ | 18,505,735 | $ | 14,837,252 | ||||
|
Operating costs and expenses:
|
||||||||
|
Cost of revenues (excluding depreciation and amortization)
|
7,069,788 | 5,461,982 | ||||||
|
Product development
|
1,786,248 | 1,526,165 | ||||||
|
Sales and marketing
|
3,507,644 | 2,960,868 | ||||||
|
Other general and administrative expenses
|
2,542,171 | 2,085,872 | ||||||
|
Depreciation and amortization
|
1,042,874 | 1,390,342 | ||||||
|
|
||||||||
|
Total operating costs and expenses
|
15,948,725 | 13,425,229 | ||||||
|
|
||||||||
|
Income from operations
|
2,557,010 | 1,412,023 | ||||||
|
|
||||||||
|
Other income (expense):
|
||||||||
|
Interest and other income
|
29,626 | 2,716 | ||||||
|
Interest and other expense
|
(9,468 | ) | (11,216 | ) | ||||
|
|
||||||||
|
Total other income (expense)
|
20,158 | (8,500 | ) | |||||
|
|
||||||||
|
|
||||||||
|
Income before income tax provision
|
2,577,168 | 1,403,523 | ||||||
|
Income tax provision
|
1,051,411 | 596,659 | ||||||
|
|
||||||||
|
Net income
|
$ | 1,525,757 | $ | 806,864 | ||||
|
|
||||||||
|
|
||||||||
|
Net income per share:
|
||||||||
|
Basic
|
$ | 0.07 | $ | 0.04 | ||||
|
|
||||||||
|
Diluted
|
$ | 0.07 | $ | 0.04 | ||||
|
|
||||||||
|
|
||||||||
|
Weighted average shares of common stock outstanding:
|
||||||||
|
Basic
|
21,837,334 | 21,675,763 | ||||||
|
|
||||||||
|
Diluted
|
22,969,406 | 22,130,145 | ||||||
|
|
||||||||
2
| Accumulated Other | Total | |||||||||||||||||||
| Common Stock | Accumulated | Comprehensive | Shareholders | |||||||||||||||||
| Shares | Amount | Deficit | Income (Loss) | Equity | ||||||||||||||||
|
Balance at December 31, 2010
|
21,805,235 | $ | 97,227,198 | $ | (40,431,443 | ) | $ | (5,417 | ) | $ | 56,790,338 | |||||||||
|
|
||||||||||||||||||||
|
Net income
|
| | 1,525,757 | | 1,525,757 | |||||||||||||||
|
|
||||||||||||||||||||
|
Unrealized gain on investments
in marketable securities.
|
| | | 3,699 | 3,699 | |||||||||||||||
|
|
||||||||||||||||||||
|
Stock based compensation expense
|
| 189,794 | | | 189,794 | |||||||||||||||
|
|
||||||||||||||||||||
|
Exercise of stock options
|
126,300 | 198,988 | | | 198,988 | |||||||||||||||
|
|
||||||||||||||||||||
|
|
||||||||||||||||||||
|
Balance at March 31, 2011
|
21,931,535 | $ | 97,615,980 | $ | (38,905,686 | ) | $ | (1,718 | ) | $ | 58,708,576 | |||||||||
|
|
||||||||||||||||||||
3
| Three Months Ended March 31, | ||||||||
| 2011 | 2010 | |||||||
|
OPERATING ACTIVITIES:
|
||||||||
|
Net income
|
$ | 1,525,757 | $ | 806,864 | ||||
|
Adjustments to reconcile net income to net cash provided by
operating activities:
|
||||||||
|
Depreciation and amortization
|
1,042,874 | 1,390,342 | ||||||
|
Stock based compensation expense
|
189,794 | 162,779 | ||||||
|
Deferred income taxes
|
1,051,411 | 596,659 | ||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts and unbilled receivables
|
(2,074,836 | ) | (2,220,597 | ) | ||||
|
Restricted cash
|
(40,022 | ) | (45,739 | ) | ||||
|
Interest receivable
|
3,885 | 235 | ||||||
|
Prepaid royalties
|
741,471 | (7,214 | ) | |||||
|
Other prepaid expenses and other current assets
|
(151,346 | ) | 82,082 | |||||
|
Other assets
|
91,381 | 47,674 | ||||||
|
Accounts payable
|
(999,887 | ) | (897,402 | ) | ||||
|
Accrued liabilities and accrued compensation and related expenses
and other long-term liabilities
|
(1,179,976 | ) | (1,127,137 | ) | ||||
|
Deferred revenue
|
3,342,058 | 2,559,507 | ||||||
|
|
||||||||
|
Net cash provided by operating activities
|
3,542,564 | 1,348,053 | ||||||
|
|
||||||||
|
|
||||||||
|
INVESTING ACTIVITIES:
|
||||||||
|
Proceeds from maturities of investments in marketable securities
|
2,135,000 | | ||||||
|
Purchases of investments in marketable securities
|
(4,727,704 | ) | | |||||
|
Payments associated with capitalized software development
|
(4,086,348 | ) | (424,248 | ) | ||||
|
Purchases of property and equipment, net
|
(708,400 | ) | (250,424 | ) | ||||
|
|
||||||||
|
Net cash used in investing activities
|
(7,387,452 | ) | (674,672 | ) | ||||
|
|
||||||||
|
|
||||||||
|
FINANCING ACTIVITIES:
|
||||||||
|
Proceeds from exercise of stock options
|
198,988 | 243,346 | ||||||
|
Payments on long-term debt
|
| (183,792 | ) | |||||
|
Payments on capital lease obligations
|
(1,609 | ) | (3,178 | ) | ||||
|
|
||||||||
|
Net cash provided by financing activities
|
197,379 | 56,376 | ||||||
|
|
||||||||
|
|
||||||||
|
Net (decrease) increase in cash and cash equivalents
|
(3,647,509 | ) | 729,757 | |||||
|
Cash and cash equivalents at beginning of period
|
17,867,860 | 12,287,059 | ||||||
|
|
||||||||
|
Cash and cash equivalents at end of period
|
$ | 14,220,351 | $ | 13,016,816 | ||||
|
|
||||||||
4
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2011 | 2010 | |||||||
|
Risk-free interest rate
|
2.37 | % | 2.39 | % | ||||
|
Expected dividend yield
|
0.0 | % | 0.0 | % | ||||
|
Expected life
|
5 years | 5 years | ||||||
|
Expected forfeiture rate
|
5 | % | 10 | % | ||||
|
Volatility
|
50 | % | 55 | % | ||||
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2011 | 2010 | |||||||
|
Cost of revenues (excluding depreciation and amortization)
|
$ | 11,166 | $ | 9,134 | ||||
|
Product development
|
39,563 | 32,087 | ||||||
|
Sales and marketing
|
47,936 | 43,779 | ||||||
|
Other general and administrative
|
91,129 | 77,779 | ||||||
|
|
||||||||
|
Total stock based compensation expense
|
$ | 189,794 | $ | 162,779 | ||||
|
|
||||||||
5
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2011 | 2010 | |||||||
|
Numerator:
|
||||||||
|
Net income
|
$ | 1,525,757 | $ | 806,864 | ||||
|
|
||||||||
|
|
||||||||
|
Denominator:
|
||||||||
|
Weighted average shares outstanding:
|
||||||||
|
Basic
|
21,837,334 | 21,675,763 | ||||||
|
Employee stock options
|
1,132,072 | 454,382 | ||||||
|
|
||||||||
|
Diluted
|
22,969,406 | 22,130,145 | ||||||
|
|
||||||||
|
|
||||||||
|
Net income per share:
|
||||||||
|
Basic
|
$ | 0.07 | $ | 0.04 | ||||
|
|
||||||||
|
Diluted
|
$ | 0.07 | $ | 0.04 | ||||
|
|
||||||||
6
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2011 | 2010 | |||||||
|
Revenues
|
||||||||
|
HealthStream Learning
|
$ | 12,986,948 | $ | 10,302,904 | ||||
|
HealthStream Research
|
5,518,787 | 4,534,348 | ||||||
|
|
||||||||
|
Total net revenue
|
$ | 18,505,735 | $ | 14,837,252 | ||||
|
|
||||||||
|
|
||||||||
|
Income from operations
|
||||||||
|
HealthStream Learning
|
$ | 4,266,534 | $ | 3,220,345 | ||||
|
HealthStream Research
|
327,014 | 159,571 | ||||||
|
Unallocated
|
(2,036,538 | ) | (1,967,893 | ) | ||||
|
|
||||||||
|
Total income from operations
|
$ | 2,557,010 | $ | 1,412,023 | ||||
|
|
||||||||
| March 31, 2011 | December 31, 2010 | |||||||
|
Segment assets *
|
||||||||
|
HealthStream Learning
|
$ | 24,431,929 | $ | 18,730,859 | ||||
|
HealthStream Research
|
26,011,466 | 26,701,566 | ||||||
|
Unallocated
|
34,646,133 | 36,578,278 | ||||||
|
|
||||||||
|
Total assets
|
$ | 85,089,527 | $ | 82,010,703 | ||||
|
|
||||||||
| * | Segment assets include restricted cash, accounts and unbilled receivables, prepaid and other current assets, other assets, capitalized software development, certain property and equipment, and intangible assets. Cash and cash equivalents and investments in marketable securities are not allocated to individual segments, and are included within Unallocated. A significant portion of property and equipment assets are included within Unallocated. |
| Amortized Cost | Unrealized Losses | Fair Value | ||||||||||
|
Corporate debt securities
|
$ | 4,539,830 | $ | (1,185 | ) | $ | 4,538,645 | |||||
|
Municipal debt securities
|
3,723,731 | (533 | ) | 3,723,198 | ||||||||
|
|
||||||||||||
|
|
$ | 8,263,561 | $ | (1,718 | ) | $ | 8,261,843 | |||||
|
|
||||||||||||
| Level 1 | Level 2 | Level 3 | ||||||||||
|
Investments in marketable securities
|
$ | 8,261,843 | $ | | $ | | ||||||
7
| | Revenues of $18.5 million in the first quarter of 2011, up 25% over the first quarter of 2010 | ||
| | Operating income of $2.6 million in the first quarter of 2011, up 81% over the first quarter of 2010 | ||
| | Net income of $1.5 million up 89% from net income of $807,000 in the first quarter of 2010 and diluted earnings per share (EPS) of $0.07 per share in the first quarter of 2011, up 75% from diluted EPS of $0.04 per share in the first quarter of 2010 | ||
| | Adjusted EBITDA of $3.8 million in the first quarter of 2011, up 28% from $3.0 million in the first quarter of 2010 | ||
| | HealthStream acquires 50% ownership in Advanced Video System (AVS) product, which will serve as the foundation for SimView, the debriefing component of SimCenter |
8
| | Revenue recognition | ||
| | Accounting for income taxes | ||
| | Product development costs and related capitalization | ||
| | Goodwill, intangibles, and other long-lived assets | ||
| | Allowance for doubtful accounts | ||
| | Accrual for service credits | ||
| | Stock based compensation | ||
| | Nonmonetary exchange of content rights and deferred service credits |
9
10
11
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2011 | 2010 | |||||||
|
Net income
|
$ | 1,525,757 | $ | 806,864 | ||||
|
Interest income
|
(22,448 | ) | (2,666 | ) | ||||
|
Interest expense
|
9,468 | 11,216 | ||||||
|
Income tax provision
|
1,051,411 | 596,659 | ||||||
|
Stock based compensation expense
|
189,794 | 162,779 | ||||||
|
Depreciation and amortization
|
1,042,874 | 1,390,342 | ||||||
|
|
||||||||
|
Adjusted EBITDA
|
$ | 3,796,856 | $ | 2,965,194 | ||||
|
|
||||||||
12
| Item 3. | Quantitative and Qualitative Disclosures about Market Risk |
13
| Item 4. | Controls and Procedures |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds. |
| (d) | ||||||||||||||||
| (c) | Maximum number (or approximate | |||||||||||||||
| Total number of shares (or | dollar value) of shares (or | |||||||||||||||
| (a) | (b) | units) purchased as part of | units) that may yet be | |||||||||||||
| Total number of shares | Average price paid per | publicly announced plans or | purchased under the plans or | |||||||||||||
| Period | (or units) purchased | share (or unit) | programs | programs | ||||||||||||
|
Month # 1 (January 1 January 31)
|
| $ | | | $ | 3,620,582 | ||||||||||
|
Month # 2 (February 1 February 28)
|
| | | | ||||||||||||
|
Month # 3 (March 1 March 31)
|
| | | | ||||||||||||
|
|
||||||||||||||||
|
Total
|
| $ | | | $ | | ||||||||||
|
|
||||||||||||||||
| Item 6. | Exhibits |
| 31.1 | Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||
| 31.2 | Certification of the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||
| 32.1 | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | ||
| 32.2 | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
14
|
HEALTHSTREAM, INC.
|
||||
| May 2, 2011 | By: | /s/ Gerard M. Hayden, Jr. | ||
| Gerard M. Hayden, Jr. | ||||
| Chief Financial Officer | ||||
15
| 31.1 | Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| 31.2 | Certification of the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| 32.1 | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 32.2 | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
16
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|